Wa'el Hashad Wa'el Hashad, CEO, Longeveron Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

Patient characteristics are consistent with other DLB studies -PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, ...

Third Quarter, Recent Business Highlights and Upcoming Milestones Neurodegenerative Diseases Portfolio Alzheimer's Disease PRX012 ... approximately 260 patients in the ASCENT clinical trials Poster ...

confirming enrollment of individuals with mild-to-moderate DLB This poster is available on the Company's website Continued enrollment in Phase 2 START study (NCT05531656) in early Alzheimer's disease ...

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Two posters were presented by Annovis' President and CEO, Dr. Maria Maccecchini, focusing on the company's lead drug candidate bunta ...

Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Al ...

Baseline characteristics of the 130 participants enrolled in the study, as described in the poster: “DLB is one of the most common forms of dementia and a complex neurological condition. Symptoms ...

Julianna LeMieux and Uduak Thomas discuss their time at the ASHG meeting in Denver and some of the trends that they are ...